Aimmune Therapeutics Announces Phase 2 Follow-On Study of AR101 for the Treatment of Peanut Allergy Demonstrated Increased Desensitization and Improved Tolerability with Low-Dose Maintenance Read more about Aimmune Therapeutics Announces Phase 2 Follow-On Study of AR101 for the Treatment of Peanut Allergy Demonstrated Increased Desensitization and Improved Tolerability with Low-Dose Maintenance
Aimmune Therapeutics Announces Fourth Quarter and Full Year 2015 Financial Results and Provides Corporate Update Read more about Aimmune Therapeutics Announces Fourth Quarter and Full Year 2015 Financial Results and Provides Corporate Update
Aimmune Therapeutics to Participate in Two Upcoming Investor Conferences in March Read more about Aimmune Therapeutics to Participate in Two Upcoming Investor Conferences in March
Aimmune Therapeutics to Announce Fourth Quarter and Full Year 2015 Financial Results on Thursday, March 3, 2016 Read more about Aimmune Therapeutics to Announce Fourth Quarter and Full Year 2015 Financial Results on Thursday, March 3, 2016
Aimmune Therapeutics Announces Presentation at the 2016 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting Read more about Aimmune Therapeutics Announces Presentation at the 2016 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting
Aimmune Therapeutics to Present at the 18th Annual BIO CEO & Investor Conference Read more about Aimmune Therapeutics to Present at the 18th Annual BIO CEO & Investor Conference
Aimmune Therapeutics Enrolls First Patient in Phase 3 PALISADE Trial of AR101 for the Treatment of Peanut Allergy Read more about Aimmune Therapeutics Enrolls First Patient in Phase 3 PALISADE Trial of AR101 for the Treatment of Peanut Allergy
Aimmune Therapeutics to Present at the 34th Annual J.P. Morgan Healthcare Conference Read more about Aimmune Therapeutics to Present at the 34th Annual J.P. Morgan Healthcare Conference
Aimmune Therapeutics Appoints Jeffrey H. Knapp as Chief Operating Officer Read more about Aimmune Therapeutics Appoints Jeffrey H. Knapp as Chief Operating Officer
Aimmune Therapeutics to Present at the Piper Jaffray 27th Annual Healthcare Investor Conference Read more about Aimmune Therapeutics to Present at the Piper Jaffray 27th Annual Healthcare Investor Conference
